IMPACT OF GUSELKUMAB INDUCTION THERAPY ON HISTOLOGIC AND COMBINED HISTOLOGIC AND ENDOSCOPIC OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: WEEK 12 RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
Julian Panés 1
Bruce E. Sands 2
Laurent Peyrin-Biroulet 3
Shadi Yarandi 4
Gary KH Huang 4
Matthew Germinaro 4
Sunandini Sridhar 4
Patrick Branigan 4
Ye Miao 4
Hongyan Zhang 4
Xavier Hebuterne 5
Tibor Gyokeres 6
Fumihito Hirai 7
Tadakazu Hisamatsu 8
David T. Rubin 9
Brian G. Feagan 10
1 Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
2 Icahn School of Medicine at Mount Sinai, New York, United States
3 Nancy University Hospital, Université de Lorraine, Nancy, France
4 Janssen Research & Development, LLC, Spring House, United States
5 CHU de Nice and University Côte d’Azur, Nice, France
6 North-Pest Central Hospital, Military Hospital, Budapest, Hungary
7 Fukuoka University Hospital, Fukuoka, Japan
8 Kyorin University, Tokyo, Japan
9 University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, United States
10 Alimentiv Inc, London, Canada
Topic
Endoscopy, Histopathology, IBD
Session
IL-23-Blockers in IBD: Part 2
Conference
UEG Week 2023
Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]